Orphazyme have announced that the U.S Food and Drug Administration (FDA) have granted the drug, arimoclomol, Fast Track designation.
The drug has been developed as a potential treatment for sporadic inclusion body myositis (sIBM). Fast Track designation is designed to expedite the development and review of drugs in the US.
We can expect results from the current phase 2/3 trial in the first half of 2021.
Read the press release from Orphazyme here.